**WHAT IS CLAIMED IS:**

**1.** A compound according to formula I

**I**

wherein

Ind is unsubstituted indol-3-yl, indol-3-yl monosubstituted by OH, OA, CN, Hal, $COR^2$ or $CH_2R^2$, or indol-3-yl polysubstituted by OH, OA, CN, Hal, $COR^2$, $CH_2R^2$ or combinations thereof;

$R^1$ is benzofuran-5-yl, ~~2,3-dihydrobenzofuran-5-yl, chroman-6-yl,~~ chroman-4-on-6-yl, 3-chromen-6-yl or chromen-4-on-6-yl, which in each case is unsubstituted or monosubstituted by CN, $CH_2OH$, $CH_2OA$ or $COR^2$;

Q is $C_mH_{2m}$;

Z is ~~N or CR³~~;

A is alkyl having 1-6 C atoms;

Hal is F, Cl, Br or I;

$R^2$ is OH, OA, $NH_2$, NHA or $NA_2$;

$R^3$ is H, OH or OA; and

m is 2, 3 or 4; or

a physiologically acceptable salt thereof.

**2.** A compound according to claim 1, wherein said compound is:

(a) 1-[4-(5-methoxyindol-3-yl)butyl]-4-(2-hydroxymethylbenzofuran-5-yl)piperazine or a physiologically acceptable salt thereof;

~~(b) 1-[4-(5-carbamoylindol-3-yl)butyl]-4-hydroxy-4-(2,3-dihydrobenzofuran-5-yl)piperidine or a physiologically acceptable salt thereof;~~

~~(c) 1-[4-(5-carbamoylindol-3-yl)butyl]-4-(2,3-dihydrobenzofuran-5-yl)piperidine or a physiologically acceptable salt thereof;~~

~~(d) 1-[4-(5-methoxyindol-3-yl)butyl]-4-(2,3-dihydrobenzofuran-5-yl)piperazine or a physiologically acceptable salt thereof;~~

(e) 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-ethoxycarbonylbenzofuran-5-yl)piperazine or a physiologically acceptable salt thereof;

(f) 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or a physiologically acceptable salt thereof;

~~(g) 1-[4-(5-methoxyindol-3-yl)butyl]-4-(chroman-6-yl)piperazine or a physiologically acceptable salt thereof;~~

~~or~~

~~(h) 1-[4-(5-hydroxyindol-3-yl)butyl]-4-(chroman-6-yl)piperazine or a physiologically acceptable salt thereof.~~

**3.** A compound according to claim 1, wherein Ind is unsubstituted indol-3-yl, indol-3-yl monosubstituted by OH, OA, CN, Hal, $COR^2$ or $CH_2R^2$, or indol-3-yl disubstituted by OH, OA, CN, Hal, $COR^2$ or $CH_2R^2$.

**4.** A compound according to claim 1, wherein Ind is indol-3-yl monosubstituted in the 5-position by OH, OA, CN, Hal, $COR^2$ or $CH_2R^2$.

**5.** A compound according to claim 1, wherein Ind is indol-3-yl monosubstituted in the 4-, 6- or 7-position by OH, OA, CN, Hal, $COR^2$ or $CH_2R^2$.

**6.** A compound according to claim 1, wherein A is methyl or ethyl.

7. A compound according to claim 1, wherein $R^1$ is benzofuran-5-yl, ~~2,3-dihydrobenzofuran-5-yl, chroman-6-yl~~ or chroman-4-on-6-yl which, in each case is unsubstituted or monosubstituted by $-CH_2OH$, $-CONH_2$, $-CO_2A$ or $-CO_2NHA$.

8. A compound according to claim 1, wherein Q is $-(CH_2)_4-$.

9. A compound according to claim 1, wherein Z is -N-, -C(OH)- or -CH-.

~~10~~ 9. A compound according to claim 1, wherein Ind is indol-3-yl substituted in the 5-position by OH or OA.

~~11~~ 10. A compound according to claim 1, wherein Ind is indol-3-yl substituted in the 5-position by $CONH_2$ or CN.

~~12~~ 11. A compound according to claim 1, wherein ~~Z is N and~~ $R^1$ is unsubstituted benzofuran-5-yl or ~~benzo-5-yl~~ benzofuran-5-yl substituted by CN, $CH_2OH$, $CH_2OA$ or $COR^2$.

13. A compound according to claim 1, wherein Z is -CH(OH)-.

14. A compound according to claim 1, wherein Z is N and $R^1$ is 2,3-dihydrobenzofuran-5-yl.

15. A compound according to claim 1, wherein Z is N and $R^1$ is chroman-6-yl.

~~16~~ 12. A compound according to claim 1, wherein ~~Z is N and~~ $R^1$ is chromen-4-on-6-yl.

~~17~~ 16. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

18. A composition according to claim 17, wherein said compound is present in an amount of 0.2-500 mg.

19. A method of treating tension, depression, psychosis or side effects associated with the treatment of hypertension, comprising administering a compound according to claim 1.

20. A method of treating acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome, undesired puerperal lactation, or cerebral disorders, comprising administering a compound according to claim 1.

21. A method of treating migraines, comprising administering a compound according to claim 1.

22. A method according to claim 21, wherein said compound is administered in a daily dosage of 0.001-0.005 mg/kg of body weight.